Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
8.29
+0.30 (3.75%)
Apr 17, 2026, 4:00 PM EDT - Market closed
Fulcrum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
552.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 80.00M | 77.20M | 2,752.05% |
| Dec 31, 2023 | 2.81M | -3.54M | -55.77% |
| Dec 31, 2022 | 6.34M | -12.82M | -66.90% |
| Dec 31, 2021 | 19.16M | 10.34M | 117.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 205.07M |
| Verastem | 30.91M |
| Aclaris Therapeutics | 7.83M |
| Adlai Nortye | 5.40M |
| Upstream Bio | 2.85M |
| Shattuck Labs | 1.00M |
| Lyell Immunopharma | 36.00K |
FULC News
- 4 weeks ago - MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease - GlobeNewsWire
- 6 weeks ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 - GlobeNewsWire
- 7 weeks ago - Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 3 months ago - Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire